Emerging role of semaphorin-3A in autoimmune diseases

[1]  A. La Cava,et al.  Editorial: Innate Immunity Pathways in Autoimmune Diseases , 2019, Front. Immunol..

[2]  P. Tak,et al.  Class 3 semaphorins modulate the invasive capacity of rheumatoid arthritis fibroblast-like synoviocytes , 2018, Rheumatology.

[3]  Z. Vadasz,et al.  Semaphorin 3A: Is a key player in the pathogenesis of asthma. , 2017, Clinical immunology.

[4]  M. Etemadifar,et al.  Decreased expression of Sema3A, an immune modulator, in blood sample of multiple sclerosis patients. , 2017, Gene.

[5]  X. Zhang,et al.  [Expression and Clinical Significance of Semaphorin 3A in serum and mononuclear cells in patients with systemic lupus erythematosus]. , 2017, Zhonghua yi xue za zhi.

[6]  Shiyang Guan,et al.  Interleukin-35: a Potential Therapeutic Agent for Autoimmune Diseases , 2016, Inflammation.

[7]  D. Ye,et al.  Emerging role of adipokines in systemic lupus erythematosus , 2016, Immunologic research.

[8]  D. Sikorska,et al.  SAT0223 Soluble Semaphorin 3A and Neuropilin-1: New Markers for Dysregulation of Angiogenesis in Systemic Sclerosis? , 2016 .

[9]  A. Drosos,et al.  SAT0222 B Cell Depletion Therapy in Systemic Sclerosis Associated Interstitial Lung Disease. A Multicenter, Open Label, Comparative Study with A Follow up of 94 Patient-Years , 2016 .

[10]  E. Toubi,et al.  A2.01 The expansion of CD25highIL-10highFOXP3high B regulatory cells is in association with sle disease activity , 2016 .

[11]  P. Tak,et al.  A7.09 Class 3 semaphorins modulate the invasive capacity of rheumatoid arthritis fibroblast-like synoviocytes , 2016 .

[12]  X. Montalban,et al.  Differential expression of sema3A and sema7A in a murine model of multiple sclerosis: Implications for a therapeutic design. , 2016, Clinical immunology.

[13]  R. Soares,et al.  Decreased expression of neuropilin-1 as a novel key factor contributing to peripheral microvasculopathy and defective angiogenesis in systemic sclerosis , 2015, Annals of the rheumatic diseases.

[14]  H. Hartung,et al.  Targeting semaphorins in MS as a treatment strategy to promote remyelination: A tale of mice, rats and men , 2015, Multiple sclerosis.

[15]  G. Slobodin,et al.  The Expansion of CD25highIL-10highFoxP3high B Regulatory Cells Is in Association with SLE Disease Activity , 2015, Journal of immunology research.

[16]  S. Cajal,et al.  Expression of semaphorin 3A, semaphorin 7A and their receptors in multiple sclerosis lesions , 2015, Multiple sclerosis.

[17]  D. Rimar,et al.  Semaphorin 3A, a potential immune regulator in Familial Mediterranean Fever , 2015, Pediatric Rheumatology.

[18]  S. Kim.  Immunological function of Blimp-1 in dendritic cells and relevance to autoimmune diseases , 2015, Immunologic Research.

[19]  Manuel A. Friese,et al.  Immunopathology of multiple sclerosis , 2015, Nature Reviews Immunology.

[20]  T. Rainis,et al.  The Involvement of Immune Semaphorins in the Pathogenesis of Inflammatory Bowel Diseases (IBDs) , 2015, PloS one.

[21]  D. Rimar,et al.  Semaphorin 3A: an immunoregulator in systemic sclerosis , 2015, Rheumatology International.

[22]  D. Rimar,et al.  A6.14 Semaphorin 3A, an immunoregulator and potential biomarker for disease severity in systemic sclerosis , 2015 .

[23]  I. F. D. Larrinoa.  Lo mejor del año en lupus eritematoso sistémico , 2015 .

[24]  I. F. Larrinoa,et al.  What is new in systemic lupus erythematosus. , 2015, Reumatologia clinica.

[25]  Í. Rúa-Figueroa Fernández de Larrinoa.  What is new in systemic lupus erythematosus. , 2015, Reumatologia clinica.

[26]  X. Corbella,et al.  Mortality and survival in systemic sclerosis: systematic review and meta-analysis. , 2014, Seminars in arthritis and rheumatism.

[27]  D. Rimar,et al.  AB0195 Semaphorin 3A as A Possible Immunoregulator in Systemic Sclerosis , 2014 .

[28]  M. Matucci Cerinic,et al.  AB0194 Ll-37: A New Marker for Interstitial Lung Disease (ILD) in Systemic Sclerosis (SSC)? , 2014 .

[29]  I. Rosner,et al.  A regulatory role for CD72 expression on B cells in systemic lupus erythematosus. , 2014, Seminars in arthritis and rheumatism.

[30]  T. Malek,et al.  The importance of regulatory T‐cell heterogeneity in maintaining self‐tolerance , 2014, Immunological reviews.

[31]  Cong Yu,et al.  Diagnostic criteria for systemic lupus erythematosus: a critical review. , 2014, Journal of autoimmunity.

[32]  Z. Vadasz,et al.  Semaphorins: Their Dual Role in Regulating Immune-Mediated Diseases , 2014, Clinical Reviews in Allergy & Immunology.

[33]  S. Zheng,et al.  Targeting T-helper 9 cells and interleukin-9 in autoimmune diseases. , 2013, Cytokine & growth factor reviews.

[34]  T. Hirano,et al.  AB0114 Semaphorin3a and semaphorin4d in rheumatoid arthritis. , 2013 .

[35]  Xavier Montalban,et al.  Semaphorins 3A and 7A: potential immune and neuroregenerative targets in multiple sclerosis. , 2013, Trends in molecular medicine.

[36]  H. Datta,et al.  Changes in bone density and bone turnover in patients with rheumatoid arthritis treated with rituximab, a B cell depleting monoclonal antibody (HORUS TRIAL) , 2013, BMC Musculoskeletal Disorders.

[37]  S. Zheng,et al.  Emerging role of interleukin-22 in autoimmune diseases. , 2013, Cytokine & growth factor reviews.

[38]  Y. Goshima,et al.  Decreased Semaphorin3A expression correlates with disease activity and histological features of rheumatoid arthritis , 2013, BMC Musculoskeletal Disorders.

[39]  H. Takayanagi,et al.  Bone cell communication factors and Semaphorins. , 2012, BoneKEy reports.

[40]  E. Toubi,et al.  Semaphorin 3A – a marker for disease activity and a potential putative disease-modifying treatment in systemic lupus erythematosus , 2012, Lupus.

[41]  G. Neufeld,et al.  Semaphorin 3A is a marker for disease activity and a potential immunoregulator in systemic lupus erythematosus , 2012, Arthritis Research & Therapy.

[42]  R. Ransohoff,et al.  Innate immunity in the central nervous system. , 2012, The Journal of clinical investigation.

[43]  J. Gran,et al.  Differences between rheumatologists and other internists regarding diagnosis and treatment of systemic lupus erythematosus. , 2012, Rheumatology.

[44]  Y. Nakatsuji,et al.  The role of immune semaphorins in multiple sclerosis , 2011, FEBS letters.

[45]  E. Sabo,et al.  The involvement of immune semaphorins and neuropilin-1 in lupus nephritis , 2011, Lupus.

[46]  J. Carrillo-Ruiz,et al.  Multiple sclerosis: An overview of the disease and current concepts of its pathophysiology , 2011 .

[47]  P. Ravassard,et al.  Class 3 semaphorins influence oligodendrocyte precursor recruitment and remyelination in adult central nervous system. , 2011, Brain : a journal of neurology.

[48]  K. Nave,et al.  Inhibition of CNS Remyelination by the Presence of Semaphorin 3A , 2011, The Journal of Neuroscience.

[49]  M. Petri,et al.  Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial , 2011, The Lancet.

[50]  B. Solomon,et al.  Neuropilin-1 attenuates autoreactivity in experimental autoimmune encephalomyelitis , 2011, Proceedings of the National Academy of Sciences.

[51]  S. Schneider‐Schaulies,et al.  Measles virus modulates dendritic cell/T‐cell communication at the level of plexinA1/neuropilin‐1 recruitment and activity , 2011, European journal of immunology.

[52]  D. Hafler,et al.  Human regulatory T cells in autoimmune diseases. , 2010, Current opinion in immunology.

[53]  A. Catalano.  The Neuroimmune Semaphorin-3A Reduces Inflammation and Progression of Experimental Autoimmune Arthritis , 2010, The Journal of Immunology.

[54]  D. Attias,et al.  Neuropilins and semaphorins - from angiogenesis to autoimmunity. , 2010, Autoimmunity reviews.

[55]  V. Barresi,et al.  Increased ratio of vascular endothelial growth factor to semaphorin3A is a negative prognostic factor in human meningiomas , 2010, Neuropathology : official journal of the Japanese Society of Neuropathology.

[56]  M. Tessier-Lavigne,et al.  Semaphorins guide the entry of dendritic cells into the lymphatics by activating myosin II , 2010, Nature Immunology.

[57]  M. Nishioka,et al.  Clinical Significance of Serum Levels of Vascular Endothelial Growth Factor, Angiopoietin-1, and Angiopoietin-2 in Patients with Rheumatoid Arthritis , 2010, The Journal of Rheumatology.

[58]  T. Randall,et al.  Effector and regulatory B cells: modulators of CD4+ T cell immunity , 2010, Nature Reviews Immunology.

[59]  A. Kumanogoh,et al.  Regulation of immune cell responses by semaphorins and their receptors , 2010, Cellular and Molecular Immunology.

[60]  M. Khamashta,et al.  Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review , 2008, Annals of the rheumatic diseases.

[61]  R. Blasczyk,et al.  27-OR: Soluble semaphorin 3A regulates the immune response , 2009 .

[62]  S. Kaveri,et al.  Surveillance of antigen-presenting cells by CD4+ CD25+ regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications. , 2009, The American journal of pathology.

[63]  L. Ivashkiv,et al.  Expression and function of semaphorin 3A and its receptors in human monocyte-derived macrophages. , 2009, Human immunology.

[64]  S. Šatkauskas,et al.  The many faces of semaphorins: from development to pathology , 2009, Cellular and Molecular Life Sciences.

[65]  Iain B McInnes,et al.  Evidence that cytokines play a role in rheumatoid arthritis. , 2008, The Journal of clinical investigation.

[66]  A. Chédotal,et al.  Plexin-A4 negatively regulates T lymphocyte responses. , 2008, International immunology.

[67]  R. Testa,et al.  Semaphorin3A signaling controls Fas (CD95)-mediated apoptosis by promoting Fas translocation into lipid rafts. , 2008, Blood.

[68]  Atsushi Kumanogoh,et al.  Semaphorins and their receptors in immune cell interactions , 2008, Nature Immunology.

[69]  H. Kikutani,et al.  Immune Semaphorins: Novel Features of Neural Guidance Molecules , 2008, Journal of Clinical Immunology.

[70]  Bernard Zalc,et al.  Semaphorin 3A and 3F: key players in myelin repair in multiple sclerosis? , 2007, Brain : a journal of neurology.

[71]  J. Ménard,et al.  Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction. , 2007, Clinical immunology.

[72]  T. Medsger,et al.  Changes in causes of death in systemic sclerosis, 1972–2002 , 2007, Annals of the rheumatic diseases.

[73]  I. Konishi,et al.  Expression of semaphorins, vascular endothelial growth factor, and their common receptor neuropilins and alleic loss of semaphorin locus in epithelial ovarian neoplasms: increased ratio of vascular endothelial growth factor to semaphorin is a poor prognostic factor in ovarian carcinomas. , 2006, Human pathology.

[74]  S. Chandran,et al.  A Novel Role for Sema3A in Neuroprotection from Injury Mediated by Activated Microglia , 2006, The Journal of Neuroscience.

[75]  A. Barzilai,et al.  Immunosuppressive role of semaphorin‐3A on T cell proliferation is mediated by inhibition of actin cytoskeleton reorganization , 2006, European journal of immunology.

[76]  M. Faronato,et al.  Semaphorin-3A is expressed by tumor cells and alters T-cell signal transduction and function. , 2006, Blood.

[77]  Kazuhiro Suzuki,et al.  Semaphorins in the Immune System , 2005 .

[78]  Y. Kanakura,et al.  Negative regulation of platelet function by a secreted cell repulsive protein, semaphorin 3A. , 2004, Blood.

[79]  Till Acker,et al.  Uncontrolled Expression of Vascular Endothelial Growth Factor and Its Receptors Leads to Insufficient Skin Angiogenesis in Patients With Systemic Sclerosis , 2004, Circulation research.

[80]  D. Pleasure,et al.  Induction of neuropilins-1 and -2 and their ligands, Sema3A, Sema3F, and VEGF, during Wallerian degeneration in the peripheral nervous system , 2003, Experimental Neurology.

[81]  C. Lau,et al.  Pathogenesis of systemic lupus erythematosus , 2003, Journal of clinical pathology.

[82]  M. Weller,et al.  Human malignant glioma cells express semaphorins and their receptors, neuropilins and plexins , 2003, Glia.

[83]  A. Püschel,et al.  The function of semaphorins during nervous system development. , 2003, Frontiers in bioscience : a journal and virtual library.

[84]  G. Villegas,et al.  Ontogeny of semaphorins 3A and 3F and their receptors neuropilins 1 and 2 in the kidney. , 2002, Mechanisms of Development.

[85]  Y. Konttinen,et al.  Increased but imbalanced expression of VEGF and its receptors has no positive effect on angiogenesis in systemic sclerosis skin. , 2002, Clinical and experimental rheumatology.

[86]  M. Conforti,et al.  Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers , 2002, Arthritis research.

[87]  J. Verhaagen,et al.  Injury-Induced Class 3 Semaphorin Expression in the Rat Spinal Cord , 2002, Experimental Neurology.

[88]  M. Gassmann,et al.  HIF-1 mediated upregulation of VEGF and VEGF-R in systemic sclerosis (SSc): Imbalance with angiostatic factors suggests VEGF as a novel option for the treatment of ischemia in patients with SSc , 2002, Arthritis Research.

[89]  T. Yagi,et al.  Requirement of neuropilin 1-mediated Sema3A signals in patterning of the sympathetic nervous system. , 2002, Development.

[90]  R. Rudick,et al.  Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. , 2002, The New England journal of medicine.

[91]  J. Goverman,et al.  A Pathogenic Role for Myelin-Specific Cd8+ T Cells in a Model for Multiple Sclerosis , 2001, The Journal of experimental medicine.

[92]  A. Elhabazi,et al.  Biological Activity of Soluble CD100. II. Soluble CD100, Similarly to H-SemaIII, Inhibits Immune Cell Migration1 2 , 2001, The Journal of Immunology.

[93]  M. Taniguchi,et al.  Expression of class 3 semaphorins and neuropilin receptors in the developing mouse tooth , 2001, Mechanisms of Development.

[94]  V. Gagliardini,et al.  Semaphorin III Can Induce Death in Sensory Neurons , 1999, Molecular and Cellular Neuroscience.

[95]  R. Kalb,et al.  Plexin-Neuropilin-1 Complexes Form Functional Semaphorin-3A Receptors , 1999, Cell.

[96]  Jacqueline Palace,et al.  The effect of anti-α4 integrin antibody on brain lesion activity in MS , 1999, Neurology.

[97]  S. Soker,et al.  Neuropilin-1 Mediates Collapsin-1/Semaphorin III Inhibition of Endothelial Cell Motility , 1999, The Journal of cell biology.

[98]  M. Poo,et al.  Unified Nomenclature for the Semaphorins/Collapsins , 1999, Cell.

[99]  A. Koch,et al.  Angiogenesis: Implications for rheumatoid arthritis , 1998 .

[100]  T. Yagi,et al.  Disruption of Semaphorin III/D Gene Causes Severe Abnormality in Peripheral Nerve Projection , 1997, Neuron.

[101]  A. Silman,et al.  Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. , 1996, British journal of rheumatology.

[102]  W. Snider,et al.  The guidance molecule Semaphorin III is expressed in regions of spinal cord and periphery avoided by growing sensory axons , 1995, The Journal of comparative neurology.

[103]  R. Adams,et al.  Murine semaphorin D/collapsin is a member of a diverse gene family and creates domains inhibitory for axonal extension , 1995, Neuron.

[104]  C. Shatz,et al.  Sernaphorin III can function as a selective chemorepellent to pattern sensory projections in the spinal cord , 1995, Neuron.

[105]  C. Goodman,et al.  The semaphorin genes encode a family of transmembrane and secreted growth cone guidance molecules , 1993, Cell.

[106]  D. Raible,et al.  Collapsin: A protein in brain that induces the collapse and paralysis of neuronal growth cones , 1993, Cell.

[107]  T. Medsger,et al.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. , 1988, The Journal of rheumatology.

[108]  F. Quismorio,et al.  T Lymphocyte Subsets in Systemic Lupus Erythematosus , 1983 .